BioCatalyst

HS-20093, Gemcitabine combined with docetaxel — catalyst calendar

1 verified catalyst event(s) referencing HS-20093, Gemcitabine combined with docetaxel, each linked to its official source. Verified as of 2026-06-22.

Upcoming

DateEventCompanyDrugOfficial source & verification
2026-08-31
in 2mo
ESTIMATED
 READOUT
Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment
Phase 3 · Osteosarcoma
 Hansoh BioMedical R&D Company HS-20093, Gemcitabine combined with doce ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.